DDReg Pharma Pvt Ltd

DDReg Pharma Pvt Ltd Incepted in the year 2009, the company is involved in a wide variety of regulatory & drug safety assignments which span across global markets.

DDReg is a global life sciences consulting firm specializing in regulatory affairs, pharmacovigilance, and quality services, accelerating product registrations and ensuring compliance through smart RegTech and deep industry expertise. Rich subject matter expertise gets combined with cutting edge technology solutions providing end to end support across pharma value chain. The company supports globa

l pharmaceutical organizations for their needs to address regulatory challenges pertaining to Biologicals, Complex formulations, INDs, NDAs and Generics, Consumer Healthcare products and Medical Devices, in highly regulated markets as well as in complex emerging markets. The services portfolio includes Document management, Dossier support, pre-Approval and Post MA regulatory support, Submission management, Regulatory Intelligence, Regulatory Strategies, Feasibility Studies, Dossier compilation, submissions, Agency follow ups and approvals. The Drug Safety Vertical supports global organizations to manage their worldwide Safety Obligations by way of Case Management, Aggregate Reporting, Safety Compliances, Signal Detection and Risk Management. Functional and Operational Excellence are manifested through Strong Quality Management System, and Efficient Project Management.

23/05/2026

In Ep. 01 of The Regulator's Perspective covered what a reviewer thinks in the first 10 minutes.

"Episode 02 goes further".

Once a reviewer decides your dossier is worth their time, what keeps that confidence through the read?

Seven specific signals that tell a reviewer this team knows their product, prepared their own narrative, and built a submission worth approving.

If you missed Episode 01? Check the profile now

Follow DDReg for the next episode.

Explore more: https://tinyurl.com/pnp66p4y



22/05/2026

Medical device registration myths are costly when left unchecked.
5 of the most common ones, busted across EU MDR, FDA, and CDSCO frameworks.

Which one surprised you most? Drop it in the comments 👇

DDReg covers medical device regulatory consulting across the EU, FDA, CDSCO, and global markets.
👉 https://tinyurl.com/pnp66p4y

When does a pet nutraceutical become a regulated veterinary product?This article breaks down the legal, regulatory, and ...
20/05/2026

When does a pet nutraceutical become a regulated veterinary product?
This article breaks down the legal, regulatory, and compliance boundaries shaping the global pet health market.

Read here: https://tinyurl.com/3sf43vuw

The regulatory strategy that starts at submission is already behind.The decisions that shape your dossier happen at form...
19/05/2026

The regulatory strategy that starts at submission is already behind.

The decisions that shape your dossier happen at formulation, pre-clinical, clinical, and CMC lock. By the time most companies bring regulations in, those decisions are history.

DDReg engages from the molecule forward, so your regulatory strategy is built into development, not bolted onto it.

Earlier regulatory input. Fewer surprises. Faster approvals.

Contact us: https://www.ddregpharma.com/

18/05/2026

Most regulatory intelligence failures do not announce themselves.

Guideline updates mid-plan. Consultation windows missed. Competitor files first. Late requirements blow the budget. Classification changes reset the strategy.

Five patterns. One root cause: intelligence that arrived too late.

VITALIC RegIntel tracks all of it in real time, before the submission clock starts.

Comment 'SIGNAL' or visit: https://tinyurl.com/46wrf8f5

17/05/2026

World Hypertension Day. 17 May 2026.

1.28 billion people are living with hypertension today. Most manageable. Many undiagnosed.

Every medicine that helps a patient manage their blood pressure exists because regulatory teams, clinical researchers, and pharmacovigilance professionals worked to make it safe, approved, and accessible.

On , we recognise everyone working to close that gap between science and patients.

"Controlling Hypertension Together."

Every regulatory team has a Type IA variation story that started with "this should be straightforward".Week 2 becomes We...
16/05/2026

Every regulatory team has a Type IA variation story that started with "this should be straightforward".

Week 2 becomes Week 5. A query arrives. Documents requested. Departments pulled in. Inspection notification lands.

Five months later- still pending variation, timeline shifted, budget exceeded.

The variation category rarely predicts the workload. The justification package & response strategy do.

DDReg manages variation submissions before "minor" stops feeling minor.
For more details: https://tinyurl.com/srjs2dm4

Comment down how many emergency meetings did your "minor" variation trigger?
Drop the number below.👇

Regulatory reviewers start at Module 2, and within the first few pages, they've already formed an impression of whether ...
15/05/2026

Regulatory reviewers start at Module 2, and within the first few pages, they've already formed an impression of whether this submission is worth a deep dive or heading for a query cycle.

What separates a strong Module 2 from a weak one:
2.3 QOS, a coherent quality narrative, not a data table dump
2.4 Nonclinical toxicology interpretation, not a catalogue of studies
2.5 Clinical Overview, a genuine risk-benefit argument, not a summary of summaries
2.7 Clinical Summaries integrated analysis across studies, not disconnected reports

If Module 2 is weak, the review starts on the back foot.

📌Save this. Share it with your regulatory writing team.

Decode the Dossier | Ep. 01 | Follow for the full series.
https://tinyurl.com/pnp66p4y

Regulatory reviewers process hundreds of dossiers.​​The gap between a First-Round Approval and a Deficiency Letter is ra...
14/05/2026

Regulatory reviewers process hundreds of dossiers.​
​
The gap between a First-Round Approval and a Deficiency Letter is rarely the science.​
It is a presentation. Completeness. And strategic awareness.​
​
What a reviewer thinks when they open your submission:​
-Is the Module 2 narrative coherent or just copied summaries?​
-Are gap justifications proactive or reactive?​
-Does this team know their product, or did a CRO prepare everything?​
​
The answers shape how much time they spend reviewing you.​
​
Save this series, continues every two weeks.​

Explore more: https://tinyurl.com/pnp66p4y

​

Most pharma companies targeting the GCC treat Saudi Arabia as one stop on a regional registration plan.It requires a sep...
13/05/2026

Most pharma companies targeting the GCC treat Saudi Arabia as one stop on a regional registration plan.
It requires a separate SFDA submission regardless of what has already been filed across other GCC markets.

Zone IVB stability data, bilingual labelling, a mandatory local representative, and four distinct pathway options.
Each one is a variable that can significantly affect your market entry timeline.

Explore the full breakdown: https://tinyurl.com/4yf3h69s

12/05/2026

Most pharma companies know WHO Prequalification opens access to global procurement markets.

DDReg's 6-step guide covers the complete WHO PQ process, from gap analysis and dossier compilation to site inspection, WHO listing, and post-approval maintenance.

DM 'WHOPREQ' to speak with our team.
Visit us: https://tinyurl.com/pnp66p4y

Address

Units 444-451, Tower B2, 4-floor Spaze-I-Tech Park, Sector 49, Sohna Road
Gurugram
122018

Telephone

+911244361505-06

Website

Alerts

Be the first to know and let us send you an email when DDReg Pharma Pvt Ltd posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to DDReg Pharma Pvt Ltd:

Shortcuts

Share

Category